TECAR Therapy on Pain and Quality of Life in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Not yet recruitingNot applicableNCT07324239
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Evaluate the effect of TECAR therapy on pain, voiding, erectile function, sleep quality and quality of life in men with chronic prostatitis/chronic pelvic pain syndrome.
Study details
- Official title
- Effect of TECAR Therapy on Pain and Quality of Life in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: a Randomized Controlled Trial
- Conditions
- Interventions
- Device: TECAR therapy
- Device: Sham TECAR therapy
- Sponsor
- Middle East University
- Start date
- 2026-01-02
- Primary completion
- 2026-04-01
- Sex
- Male
- Age range
- from 30 Years to 50 Years
- Results posted
- No results posted in this snapshot
- Countries
- Egypt
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Presence of chronic prostatitis/chronic pelvic pain symptoms for more than 6 months. * Ages will be ranged from 30 to 50 years old. Exclusion Criteria: 1. Urinary and seminal infections. 2. Recent parenteral steroid administration. 3. Prior prostate or pelvic surgery. 4. Lower urinary tract disorders such as bladder stones. 5. Implanted electronic devices as pacemakers. 6. Sensory loss over the perineum.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07324239